SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY)
INCY 105.70+2.7%Nov 5 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biotech Jim who wrote (3066)4/9/2015 6:34:43 PM
From: former_pgs  Read Replies (1) of 3202
 
Have just started looking into them and may write a very small summary, but it also looks like INCY is going to show some preclinical data on a PIM kinase inhibitor, INCB053914.

Sounds like the PIM kinase class is getting tested by some myeloma docs. Novartis has one early in the clinic (LGH447), AMGN and BIIB have some chemistry papers for PIM kinase inhibitors (i assume they're looking into the space), and AZD had one that they dropped. There was an old one from Astex (SGI-1776) that seems to have been stopped a few years ago due to cardiotoxicity.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News